168 related articles for article (PubMed ID: 17538545)
1. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
McComsey GA; O'Riordan M; Setzer B; Lebrecht D; Baron E; Walker UA
Eur J Clin Nutr; 2008 Aug; 62(8):1031-7. PubMed ID: 17538545
[TBL] [Abstract][Full Text] [Related]
2. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
[TBL] [Abstract][Full Text] [Related]
4. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA; Walker UA; Budhathoki CB; Su Z; Currier JS; Kosmiski L; Naini LG; Charles S; Medvik K; Aberg JA;
AIDS; 2010 Oct; 24(16):2507-15. PubMed ID: 20827170
[TBL] [Abstract][Full Text] [Related]
5. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
[TBL] [Abstract][Full Text] [Related]
6. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
[TBL] [Abstract][Full Text] [Related]
7. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
9. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.
Shikuma CM; Gerschenson M; Chow D; Libutti DE; Willis JH; Murray J; Capaldi RA; Marusich M
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1255-62. PubMed ID: 18844460
[TBL] [Abstract][Full Text] [Related]
12. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients.
Banasch M; Goetze O; Knyhala K; Potthoff A; Schlottmann R; Kwiatek MA; Bulut K; Schmitz F; Schmidt WE; Brockmeyer NH
AIDS; 2006 Jul; 20(11):1554-6. PubMed ID: 16847412
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
[TBL] [Abstract][Full Text] [Related]
14. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
[TBL] [Abstract][Full Text] [Related]
15. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
Hammond E; McKinnon E; Nolan D
Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
19. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.
McComsey GA; Libutti DE; O'Riordan M; Shelton JM; Storer N; Ganz J; Jasper J; Harrill D; Gerschenson M
Antivir Ther; 2008; 13(5):715-22. PubMed ID: 18771055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]